Company Filing History:
1 out of 16 
1 out of 150 
Years Active: 1995
Title: Thomas M Barnes: Innovator in Tumor Defense Mechanisms
Introduction
Thomas M Barnes is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of biotechnology, particularly in the area of tumor defense mechanisms. His work focuses on the development of proteins that play a crucial role in the body's natural defense against tumor invasion and metastasis.
Latest Patents
Thomas M Barnes holds a patent for Human PAI-2 - Minactivin, also known as Plasminogen Activator Inhibitor-2 (PAI-2). This protein acts as an inactivator of urokinase-type plasminogen activator, which is associated with invasive tumors. The patent outlines the production of minactivin through the cultivation of minactivin-producing cells in vitro, allowing for the recovery of the cell culture supernatant. By controlling the culture conditions, minactivin can be produced in a partially purified form for use in the diagnosis and treatment of tumors. The specification also details the purification of biologically active native minactivin, as well as peptides derived from minactivin and their amino acid sequences. Furthermore, it discloses methods for producing PAI-2 using recombinant DNA technology, characterizing a PAI-2 gene sequence, and expressing and purifying large quantities of biologically active PAI-2 from a recombinant host.
Career Highlights
Throughout his career, Thomas M Barnes has worked with prominent organizations such as Biotechnology Australia Pty, Ltd and The Australian National University. His expertise in biotechnology has allowed him to contribute to significant advancements in the understanding and treatment of tumors.
Collaborations
Some of his notable coworkers include Ross W Stephens and Jeffrey P Golder. Their collaborative efforts have furthered research in the field of tumor biology and treatment.
Conclusion
Thomas M Barnes is a distinguished inventor whose work on Human PAI-2 - Minactivin has the potential to impact cancer diagnosis and treatment significantly. His contributions to biotechnology continue to pave the way for advancements in tumor defense mechanisms.